Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant Tislelizumab and Chemotherapy for ESCC
NCT05984342Phase 1Recruiting
- Sponsor
- Affiliated Cancer Hospital of Shantou University Medical College
- Start
- Aug 2023
- Primary completion
- Jun 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of tislelizumab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Affiliated Cancer Hospital of Shantou University Medical College. Primary endpoint: Disease-Free Survival Rate at 1 year. Started Aug 2023; status: recruiting.
02
Drugs
tislelizumab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT05984342.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05984342.